Teva Calls 5.550% Senior Notes Due 2016 for Redemption

Teva Calls 5.550% Senior Notes Due 2016 for Redemption

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA  ) announced today that its finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for redemption its approximately $500 million outstanding principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being funded with cash on hand.

The redemption date will be March 22, 2013, and the redemption price will equal the principal amount of the notes plus a make whole premium calculated in accordance with the terms of the applicable indenture. On the redemption date, the redemption price, together with accrued and unpaid interest from February 1, 2013, to, but excluding, the redemption date, will become due and payable on the notes.

Details concerning the redemption price and the other terms and conditions of the redemption will be more fully described in a Notice of Redemption being provided to registered holders of the notes by The Bank of New York Mellon, as trustee. Holders of notes who have questions should contact Joellen McNamara of The Bank of New York Mellon at 1-212-815-5587 or via email at joellen.mcnamara@bnymellon.com, or Teva’s investor relations department at (215) 591-8912 or (011) 972-3-926-7656.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA  ) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.



Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2287565, ~/Articles/ArticleHandler.aspx, 9/1/2014 10:28:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...